Mometasone/indacaterol inhaler bests fluticasone/salmeterol combo in difficult asthma: BMJ

Written By :  MD Editorial Team
Medically Reviewed By :  Dr. Kamal Kant Kohli
Published On 2021-10-20 03:30 GMT   |   Update On 2023-10-06 12:13 GMT
Advertisement

Asthma is a prevalent chronic disease of the respiratory system and needs immediate care. Despite higher standard of care inhaled corticosteroid (ICS) or long-acting β2-agonist therapies, a substantial proportion of patients with asthma remain inadequately controlled.

A new study by Dr Kenneth Chapman and team revealed that high-dose mometasone furoate/indacaterol acetate (MF/IND) when used once a day reduced asthma exacerbations and improved lung function than fluticasone propionate/salmeterol xinafoate (FLU/SAL) that was used two times a day, in patients with inadequately controlled asthma.

Advertisement

The study demonstrates the superiority of a once-daily high-dose ICS-LABA formulation such as MF/IND as compared with twice-daily ICS-LABA as a potential treatment for asthma.

The study has been published in the journal BMJ Open Respiratory Research.

The objective of the study was to evaluate efficacy and safety of MF/IND versus FLU/SAL in patients with inadequately controlled asthma.

The study was an analysis including patients from palladium and iridium studies who received high-dose MF/IND (320/150 µg) or medium-dose MF/IND (160/150 µg) one time a day or high-dose FLU/SAL (500/50 µg) two times a day for 52 weeks. Reduction in asthma exacerbations, improvement in lung function, asthma control, and safety were evaluated for 52 weeks.

The results of the study were

• A total of, 3154 patients (high-dose MF/IND, n=1054; medium-dose MF/IND, n=1044; high-dose FLU/SAL, n=1056) were included.

• High-dose MF/IND showed 26%, 22% and 19% reductions in rate of severe, moderate or severe, and all (mild, moderate and severe) exacerbations versus high-dose FLU/SAL, respectively, over 52 weeks (all, p<0.05).

• High-dose MF/IND improved trough FEV1 versus high-dose FLU/SAL at weeks 26 (Δ, 43 mL, p=0.001) and 52 (Δ, 51 mL, p<0.001).

• Reductions in asthma exacerbation rate and improvement in trough FEV1 with medium-dose MF/IND were comparable with high-dose FLU/SAL over 52 weeks.

• All treatments improved Asthma Control Questionnaire-7 score from baseline to 52 weeks with no difference between treatments. Safety was comparable between high-dose MF/IND and high-dose FLU/SAL.

Dr Chapman and team concluded that when high-dose MF/IND used one time a day, single-inhaler, reduced asthma exacerbations and improved lung function compared to two times a day, high-dose FLU/SAL in patients with inadequately controlled asthma. Similarly, improved outcomes were seen with one time a day, medium-dose MF/IND and two times a day, high-dose FLU/SAL, but at a lower ICS dose.

Reference: 

http://dx.doi.org/10.1136/bmjresp-2020-000819

Tags:    
Article Source : BMJ Journals

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News